Dennis Ding
Stock Analyst at Jefferies
(n/a)
# 4,424
Out of 4,433 analysts
6
Total ratings
n/a
Success rate
-32.52%
Average return
Main Sectors:
Top Industries:
6 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LYRA Lyra Therapeutics | Downgrades: Hold | $10 → $0.5 | $0.37 | +36.02% | 1 | May 7, 2024 | |
| CARA Cara Therapeutics | Reiterates: Buy | $18 | $0.81 | +2,135.47% | 1 | Jun 27, 2023 | |
| CORT Corcept Therapeutics | Downgrades: Hold | $35 → $22 | $27.54 | -20.12% | 1 | Feb 15, 2023 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Buy | $24 | $20.05 | +19.70% | 1 | Dec 19, 2022 | |
| ABUS Arbutus Biopharma | Upgrades: Buy | $4 → $5 | $2.89 | +73.01% | 1 | Feb 2, 2022 | |
| ROIV Roivant Sciences | Initiates: Buy | n/a | $11.41 | - | 1 | Oct 26, 2021 |
Lyra Therapeutics
May 7, 2024
Downgrades: Hold
Price Target: $10 → $0.5
Current: $0.37
Upside: +36.02%
Cara Therapeutics
Jun 27, 2023
Reiterates: Buy
Price Target: $18
Current: $0.81
Upside: +2,135.47%
Corcept Therapeutics
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $27.54
Upside: -20.12%
NewAmsterdam Pharma Company
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $20.05
Upside: +19.70%
Arbutus Biopharma
Feb 2, 2022
Upgrades: Buy
Price Target: $4 → $5
Current: $2.89
Upside: +73.01%
Roivant Sciences
Oct 26, 2021
Initiates: Buy
Price Target: n/a
Current: $11.41
Upside: -